Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05081219 · ClinicalTrials.gov registry record · Phase 2
SNIFF - Combo INI+EMPA Trial
A Phase 2 study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT05081219 is a Phase 2 study of Alzheimer Disease and Mild Cognitive Impairment that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 47 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05081219, a Phase 2 study of Alzheimer Disease and Mild Cognitive Impairment, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed pilot study will provide safety and efficacy preliminary data regarding singular and combined effects of two therapeutic approaches, intranasal insulin and treatment with the sodium-glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin, to correct bioenergetic and vascular dysfunction in adults with preclinical Alzheimer's disease (AD) and amnestic mild cognitive impairment (aMCI) or early AD.
Conditions Studied
Interventions
- DRUG Empagliflozin 10 MG
- DRUG Insulin (Humulin® R U-100)
- DEVICE Aptar Pharma CPS Intranasal Delivery Device
- DRUG Placebo (Insulin Diluent)
- DRUG Placebo (Capsules)
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences / Wake Forest School of Medicine - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2021-09-14 |
| Est. Completion | 2024-09-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05081219
The ClinicalTrials.gov registry entry for NCT05081219 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 5 interventions - of which Empagliflozin 10 MG is the first listed.
NCT05081219 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05081219 about?
NCT05081219 is a clinical study titled "SNIFF - Combo INI+EMPA Trial". The proposed pilot study will provide safety and efficacy preliminary data regarding singular and combined effects of two therapeutic approaches, intranasal insulin and treatment with the sodium-glucose cotransporter type 2 inhibitor (SGLT2i) empagliflozin, to correct bioenergetic and vascular dysfu...
What is the current status of trial NCT05081219?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2021-09-14. Estimated completion is 2024-09-17.
What conditions does trial NCT05081219 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Cognitive Impairment.
What interventions are being tested in trial NCT05081219?
The interventions under investigation include: Empagliflozin 10 MG (DRUG), Insulin (Humulin® R U-100) (DRUG), Aptar Pharma CPS Intranasal Delivery Device (DEVICE), Placebo (Insulin Diluent) (DRUG), Placebo (Capsules) (DRUG).
Who is sponsoring clinical trial NCT05081219?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05081219 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.